Nanotechnology-based Drug Delivery Market Size & Share 2023 to 2032
Market Size by Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective), Global Forecast.
Report ID: GMI6208
|
Published Date: July 2023
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Nanotechnology-based Drug Delivery Market Size
Nanotechnology-based Drug Delivery Market size accounted for USD 95.2 billion in 2022 and is estimated to grow at a CAGR of 12.6% to reach USD 308.4 billion by end of 2032. The growing preference for precision medicines is one of the significant growth drivers for the nanotechnology-based drug delivery industry.
Nanotechnology-based Drug Delivery Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
As individuals have unique genetic makeup and varying responses to treatments, there is a rising demand for tailored therapeutic solutions. Therefore, nanotechnology-based drug delivery systems offer the ability to customize treatments based on specific patient characteristics. Also, by modifying nanoparticle properties, such as targeting ligands, size, and surface charge, personalized medicines can be developed to optimize treatment outcomes.
Nanotechnology-based drug delivery refers to the application of nanoscale materials and technologies in designing and developing systems for the targeted delivery of therapeutic agents, such as drugs, genes, or vaccines, to specific sites within the body.
COVID-19 Impact Analysis
The COVID-19 pandemic had a positive impact on the nanotechnology-based drug delivery market. The urgent requirement for effective treatments and vaccines against the virus has accelerated research and innovation in the field of drug delivery systems. Nanotechnology-based platforms have played a crucial role in the development of COVID-19 therapeutics by enabling targeted delivery, controlled release, and enhanced efficacy of antiviral drugs. For instance, according to a National Institute of Health (NIH) 2021 publication titled "Nanoparticles as an effective drug delivery system in COVID-19," nanomedicines and nano drug delivery systems have demonstrated effectiveness in treating COVID-19. As a result, the market showed a slight positive growth during pandemic. Furthermore, the pandemic has highlighted the importance of advanced drug delivery systems in responding to emerging infectious diseases. Hence, there was a growing demand for nanotechnology-based drug delivery solutions for COVID-19 and other infectious diseases.
Nanotechnology-based Drug Delivery Market Driving Factors
Nanotechnology in drug delivery market is experiencing a huge demand due to the surging prevalence of chronic diseases such as such as cancer, cardiovascular diseases, and neurological disorders. For instance, according to the Sudden Cardiac Arrest Foundation, in 2020, approximately 19.1 million deaths were attributed to CVD globally. The age-adjusted prevalence rate was 7354.1 per 100,000. Thus, nanotechnology-based drug delivery offers promising solutions to address the complexities of these diseases by delivering drugs with enhanced efficacy and reduced side effects. As a result, the demand for nanotechnology-based drug delivery systems is expected to surge, providing opportunities for businesses operating in this sector to develop innovative products and solutions to meet the growing healthcare demands.
Nanotechnology-based Drug Delivery Market Restraint
The development and implementation of nanotechnology-based drug delivery systems often involve advanced materials, complex manufacturing processes, and specialized expertise, that can lead to increased production costs. These elevated costs can pose challenges in terms of affordability and reimbursement, potentially limiting the widespread adoption of these innovative technologies. Thus, the high cost of nanotechnology-based drug delivery techniques will hamper the market share. Moreover, stringent regulatory policies will further restrict the market growth.
Nanotechnology-based Drug Delivery Market Analysis
Based on technology, the nanotechnology-based drug delivery market is segmented into nanocrystals, nanoparticles, liposomes, micelles, and other technologies. Nanoparticles dominated the global market in 2022 and will grow at 12.4% CAGR to reach USD 115.7 billion by the end of the forecast period. Continuous advancements in nanomaterials have led to the development of a diverse range of nanoparticle platforms, thereby offering flexibility and versatility in drug delivery applications. Furthermore, increasing investments from both public and private sectors, as well as collaborations between academia, industry, and research institutions, are driving the growth of nanotechnology-based drug delivery systems.
Based on application, the nanotechnology-based drug delivery market is segmented into neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, and other applications. The oncology segment accounted for 30.2% of the market share in 2022 and is projected to witness considerable growth over the analysis timeframe. Increasing prevalence of cancer is anticipated to accelerate the market growth. For instance, according to the American Cancer Society report, in 2023, more than 1.9 million new cancer cases and 609,360 cancer deaths are projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Therefore, adoption of nanotechnology-based drug delivery systems will allow for controlled and sustained release of anticancer drugs, ensuring optimal drug concentrations within the tumour over an extended period. This capability is crucial for combating cancer's complex nature and overcoming drug resistance thus, augmenting the market expansion.
North America nanotechnology-based drug delivery market accounted for 46.6% revenue share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. Factors such as increasing prevalence of chronic diseases, a high disposable income, and robust healthcare infrastructure is expected to supplement the regional growth. Also, favourable regulatory policies and initiatives in North America support the development and commercialization of nanotechnology-based drug delivery systems. Furthermore, presence of several leading pharmaceutical companies, research institutions, and academic centers that are actively involve in the research and development activities related to nanotechnology-based drug delivery systems is further expected to boost the regional market statistics.
Nanotechnology-based Drug Delivery Market Share
Major market players operating in the nanotechnology-based drug delivery market include:
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Nanotechnology-based Drug Delivery Industry News:
The nanotechnology-based drug delivery market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:
Click here to Buy Section of this Report
By Technology
By Application
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →